The Indian Pharmaceutical Market is set for continued double-digit growth. May's performance showed strong demand across all therapies. Chr...

Rising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...

We are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...

ET Wealth presents an 8-quarter earnings assessment report of various sectors. The year-on-year net profit growth for 18 sectors is present...

Shares of Alkem Laboratories will be in focus after block deals worth around Rs 930 crore saw 17.88 lakh shares traded at Rs 5,200 apiece o...

Alkem Laboratories shares experienced significant block deals totaling Rs 930 crore. Promoter family entities divested shares to a group of...

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

Venus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi ...

Global pharma major Bayer is significantly expanding its consumer healthcare presence in India, targeting the burgeoning self-care market e...

Mankind Pharma announced a significant 30 percent profit increase for the fourth quarter. This growth was fueled by strong demand for chron...

The revival was on the back of therapies, including cardiac and anti-diabetic, which grew by 19.5% and 9.7% respectively in October (over S...

According to data from AIOCD, the Indian pharma market has grown at a compound annual growth rate of 3.3% in volume terms in the past five ...